methylprednisolone sodium succinate / Generic mfg. - LARVOL DELTA

CASPR2 antibody-associated neurological syndrome after PD-1 inhibitor treatment (tislelizumab) in a patient with lung adenocarcinoma: A case report and literature review. (PubMed, J Neuroimmunol) - "The patient's neurological symptoms resolved completely within 1 week after high-dose methylprednisolone and intravenous immunoglobulin treatment, But immune checkpoint inhibitor (ICI) therapy was permanently discontinued, and the patient subsequently died at home. To our knowledge, this report describes the second documented case globally and the first associated with tislelizumab exposure. This case underscores that anti-PD-1 therapy can trigger this rare yet serious autoimmune neurological subtype."

Journal • Alzheimer's Disease • Ataxia • Brain Cancer • CNS Disorders • Cognitive Disorders • Immunology • Lung Adenocarcinoma • Lung Cancer • Movement Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CNTN

Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Bin Gu | Not yet recruiting ➔ Recruiting | Trial primary completion date: Oct 2026 ➔ Oct 2027

Enrollment open • Trial primary completion date • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation

A case of IgG4-related pia mater inflammation (PubMed, Rinsho Shinkeigaku) - "The patient was treated with intravenous methylprednisolone followed by oral prednisolone, resulting in rapid improvement of consciousness and reduction of leptomeningeal enhancement on MRI. This case represents a rare form of IgG4-related leptomeningitis in which the pia mater is the primary site of involvement. The findings underscore the importance of considering IgG4-related disease in the differential diagnosis of aseptic meningitis, particularly when imaging suggests pia mater inflammation and serum IgG4 levels are elevated."

Journal • Ataxia • CNS Disorders • Fibrosis • Immunology • Infectious Disease • Inflammation • Movement Disorders • SDC1

Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report. (PubMed, Korean J Fam Med) - "Semaglutide was discontinued, and high-dose intravenous methylprednisolone was administered. At 6 months, the optic disc edema had resolved, leaving mild disc pallor, though the visual field defect persisted. Although causality cannot be established from a single case, this report highlights the need for clinical vigilance regarding optic neuropathy in patients receiving semaglutide, particularly in the setting of rapid weight loss."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Administering Tafasitamab, Lenalidomide, and Rituximab for Follicular Lymphoma: A Single-Institution Experience From the Phase 3 inMIND Study (SOHO 2026) - "Experience from Fred Hutch demonstrates that reduced infusion durations for tafasitamab/placebo and rituximab delivered through the described rapid infusion protocol enabled a meaningful reduction in clinic time of >2 hours after cycle 1 day 1. Limiting intervals between pretreatment procedures and infusion would further enable completion of all infusions reliably in a single day. CD: cluster of differentiation, Fred Hutch: Fred Hutchinson Cancer Center, IRR: infusion-related reaction, IV: intravenous."

Clinical • P3 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Diffuse Large B-Cell Lymphoma Mimicking Vasculitis in a Patient With Gastric GIST: A Diagnostic Odyssey Resolved by Kidney Biopsy (SOHO 2026) - "Case Presentation: A 52-year-old woman with hypertension, gastric GIST on neoadjuvant imatinib, tobacco and cocaine use, and mood disorder presented with progressive fatigue, weakness, and confusion...Treatment included methylprednisolone 1 g intravenous daily for five doses, rituximab, and dose-reduced cyclophosphamide. Vincristine and anthracyclines were withheld, because of hyperbilirubinemia... Clinicians should consider lymphoproliferative disorders when evaluating multifocal CNS lesions with concurrent renal dysfunction that does not respond to initial management. Early tissue biopsy of accessible organs can provide a definitive diagnosis and prevent delays in appropriate therapy. The double-expressor immunophenotype carries prognostic significance and influenced treatment selection in this case."

Biopsy • Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Stromal Tumor • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Sarcoma • ANO1 • BCL2 • BCL6 • CD20 • IRF4 • KIT • MME

Rare Intersections: Two Cases Illustrating the Immune Complexity of Chronic Lymphocytic Leukemia Associated With Paraneoplastic Pemphigus With Ocular Involvement and Temozolomide-Induced Autoimmune Cytopenias in Concurrent Lymphoproliferative Disease (SOHO 2026) - "Despite aggressive multimodal immunosuppression (prednisone, cyclosporine, upadacitinib, intravenous methylprednisolone, IVIG, and cyclophosphamide) alongside venetoclax-obinutuzumab, he achieved near-complete MRD-negative remission but developed fulminant corneal melt with uveal prolapse requiring left eye evisceration. Venetoclax was subsequently discontinued due to severe cytopenias, and therapy was transitioned to acalabrutinib to leverage BTK inhibition for both sustained CLL control and its favorable T-cell immunomodulatory properties relevant to PNP pathogenesis. Escalation with a higher dose of upadacitinib and ruxolitinib is under consideration for refractory mucosal disease...Romiplostim was initiated, with rituximab under consideration for refractory thrombocytopenia... Together, these cases demonstrate that CLL is not a passive bystander but an active immunologic substrate that amplifies the risk of severe paraneoplastic syndromes and unmasks autoimmune..."

Clinical • Brain Cancer • Chronic Lymphocytic Leukemia • Glioblastoma • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • IGH • MGMT • RUNX1

Paraneoplastic Pemphigus With Corneal Melt Leading to Evisceration in a Patient With Chronic Lymphocytic Leukemia: Navigating Immunosuppression and Disease Control (SOHO 2026) - "Case Report: A 60-year-old man was diagnosed with immunoglobulin heavy chain variable region (IGHV)-unmutated, TP53 wild-type CLL in 2020 and remained on active surveillance until 5 years later, when progressive PNP prompted initiation of venetoclax-obinutuzumab along with immunosuppression using prednisone, cyclosporine, and upadacitinib...Despite repeated corneal glue applications, methylprednisolone, intravenous immunoglobulins (IVIG), and cyclophosphamide, he developed complete corneal melt with active uveal prolapse and markedly elevated intraocular pressure...Therapy was transitioned to acalabrutinib to leverage Bruton tyrosine kinase (BTK) inhibition for sustained CLL control alongside favorable T-cell immunomodulatory effects relevant to PNP pathogenesis...Escalation to higher dose upadacitinib with the addition of ruxolitinib is under consideration given its broader JAK inhibition profile... This case highlights the catastrophic and underappreciated ocular..."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • IGH • TP53

Medically Refractory Acute Severe Ulcerative Colitis Complicated by Cytomegalovirus Managed With Diverting Loop Ileostomy During Pregnancy: A Case Report (ACG 2026) - "Case Description/ A 23-year-old woman with a 10-year history of ulcerative pancolitis being treated with upadacitinib 45mg and prednisone 40mg was transferred from another hospital at 25 weeks gestation with 2 weeks of bloody diarrhea. She had loss of response or non-response to adalimumab, vedolizumab, ustekinumab, and prior response to infliximab induction but lost response after switching to subcutaneous maintenance...Intravenous solumedrol was started on day 1 and upadacitinib was continued...She continued infliximab and valganciclovir and tapered off prednisone outpatient...Secondly, the management of CMV colitis during pregnancy may differ from non-pregnant individuals, as ganciclovir is typically avoided due to potential risks to the fetus...Figure: Figure 1: Representative image from flexible sigmoidoscopy showing severe colitis with erythema and ulcerations. Figure: Figure 2: Picture of the patientâs ostomy wound two weeks post-op."

Case report • Clinical • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma. (PubMed, Front Oncol) - "The patient was treated with intravenous methylprednisolone (IVMP) pulse and intravenous immunoglobulin (IVIG) at initial hospitalization, followed by a slow oral prednisone taper along with monthly IVIG outpatient. Prompt recognition, exclusion of infectious mimics, and multidisciplinary management can yield meaningful visual recovery. Comprehensive neuro-ophthalmic assessment for ICI-associated neuro-ophthalmic complications including evaluation of color vision and pupillary function, documentation of fundus appearance, and additional ancillary testing with visual field and OCT analysis is essential."

Checkpoint inhibition • Journal • Cutaneous Melanoma • Genetic Disorders • Hematological Disorders • Macular Edema • Melanoma • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders • Solid Tumor

Concurrent CML and MBL in a COPD patient: a case of collision hematologic malignancies and opportunistic infection. (PubMed, Front Med (Lausanne)) - "Notably, despite the complete normalization of C-reactive protein (CRP < 0.2 mg/L), there was a paradoxical increase in the white blood cell (WBC) count to 50.2 × 109/L during treatment with high-dose intravenous methylprednisolone...The patient received treatment with imatinib (400 mg/day) and high-dose trimethoprim-sulfamethoxazole (TMP-SMX, 15-20 mg/kg/day), resulting in the resolution of respiratory symptoms within 1 week and an early molecular response by day 21, as evidenced by a reduction in BCR::ABL1 IS from 64.93% to 11.03%. In this patient with COPD undergoing systemic corticosteroid treatment, steroid-resistant lymphocytosis accompanied by WBC-CRP dissociation led to a bone marrow evaluation that revealed two concurrent clonal hematologic disorders. This single case suggests that such a pattern may warrant hematologic assessment in similar clinical settings, and that even subclinical clonal B-cell disorders may carry immunological relevance meriting..."

Journal • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Chronic Obstructive Pulmonary Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • ABL1 • CD20 • CD5 • CRP • FCER2

Lower Gastrointestinal Involvement in Adult-Onset NXP2 Antibody-Positive Dermatomyositis (ACG 2026) - "He was treated with intravenous solumedrol with overall improvement...The patient was initially trialed on adalimumab with adequate control of his muscular and GI symptoms, but developed anti-therapeutic antibodies leading to secondary non-response. Thereafter, he continued to have suboptimal control of his disease on multiple therapies including intravenous immunoglobulin and tofacitinib. Currently, he is followed closely by his GI and rheumatology providers on oral tacrolimus...Management of these symptoms is largely empiric, with Janus kinase inhibitors and vedolizumab emerging as promising treatment options...Colonoscopic findings. Patchy moderate inflammation was found in the entire examined colon, including (A) ascending colon, (B) transverse colon, (C) descending colon, and (D) sigmoid colon."

Clinical • Dermatitis • Dermatomyositis • Gastroenterology • Gastrointestinal Disorder • Immunology • Myositis • Peptic Ulcer • Vasculitis • CRP

Case Report: Severe QL1706-associated immune-related inflammatory myopathy presenting with respiratory dysfunction, bulbar weakness, ocular motility impairment, and suspected cardiac involvement. (PubMed, Front Oncol) - "Here, we report a 61-year-old woman with endometrial clear cell carcinoma who developed severe immune-related inflammatory myopathy 4 weeks after the first cycle of QL1706 combined with paclitaxel and carboplatin. The patient improved after high-dose methylprednisolone, intravenous immunoglobulin and tacrolimus. This case highlights the need for early recognition, multidisciplinary evaluation and prompt immunosuppressive treatment for severe neuromuscular immune-related adverse events during QL1706-based therapy."

Journal • Cardiovascular • Cervical Cancer • Clear Cell Carcinoma • CNS Disorders • Cognitive Disorders • Endometrial Cancer • Endometrial Clear Cell Carcinoma • Gastrointestinal Disorder • Immunology • Myasthenia Gravis • Myositis • Ocular Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Mind the Gap: Fatal AIHA Flare During Delayed CLL-Directed Therapy in a Patient With Competing Cardiovascular Priorities (SOHO 2026) - "Following two steroid-responsive AIHA episodes, venetoclax-obinutuzumab was planned but not initiated before a third recurrence occurred. Within days of recurrent hemolysis, hemoglobin precipitously declined from 12 to 6 g/dL, with LDH >1800 U/L despite escalation to IV methylprednisolone. Refractory hemolysis culminated in profound lactic acidosis (lactate >20 mmol/L) despite rituximab, IVIG, and transfusion support...Each recurrence of AIHA without definitive CLL-directed therapy represents a missed opportunity to prevent the next and potentially fatal hemolytic crisis, underscoring that treatment must be initiated proactively rather than reactively in patients with contraindications to BTKi. B-CLL: B-cell chronic lymphocytic leukemia, BTKi: Bruton tyrosine kinase inhibitor, CD: cluster of differentiation, CLL: chronic lymphocytic leukemia, IPS-E: International Prognostic Score for Early-stage CLL, IV: intravenous, IVIG: intravenous immunoglobulin, LDH: lactate..."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • CD20 • CD5 • FCER2

Asymptomatic extreme troponin elevation preceding fatal clinically suspected sintilimab-associated myocarditis: a case report. (PubMed, Front Oncol) - "A 71-year-old man with advanced gastric adenocarcinoma with liver, abdominal cavity, and retroperitoneal metastases received first-line oxaliplatin, S-1, and sintilimab on December 30, 2025...Intravenous methylprednisolone, intravenous immunoglobulin, and intensive supportive treatment were administered...This case illustrates a biomarker-first presentation of probable ICI-associated myocarditis, in which catastrophic myocardial injury was detected before typical cardiac symptoms became apparent. Absence of chest pain or dyspnea should not reassure clinicians when marked troponin elevation occurs shortly after ICI exposure."

IO biomarker • Journal • Cardiovascular • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Inflammation • Oncology • Pain • Pulmonary Disease • Solid Tumor • MB • TNNI3

Daratumumab Treatment in Severe Anti-NMDAR Encephalitis: Two Case Reports and Literature Review. (PubMed, Neurol Neuroimmunol Neuroinflamm) - "These observations suggest that specific plasma cell-targeted therapy may be beneficial in severe anti-NMDAR encephalitis, potentially through reduction of pathogenic autoantibody production. However, current evidence is limited to uncontrolled reports, and further studies are needed to clarify optimal timing, efficacy, and safety."

Journal • Review • CNS Disorders • Epilepsy • Psychiatry

Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. (PubMed, Lancet) - P=N/A | "In selected patients with permanently unresectable colorectal liver metastases, liver transplantation plus chemotherapy with organ allocation priority significantly improved survival versus chemotherapy alone. These results support the validation of liver transplantation as a new standard option for patients with permanently unresectable liver-only metastases."

Clinical • Journal • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor • Transplantation • BRAF

Acute Disseminated Encephalomyelitis Following Nivolumab Therapy for Hodgkin Lymphoma: A Case Report and Literature Review. (PubMed, Cureus) - "The patient was managed with intravenous (IV) methylprednisolone, IV immunoglobulin (IVIG), and plasmapheresis and showed clinical improvement. Serial imaging and exclusion of alternative etiologies are essential for timely diagnosis and management. Patient outcomes may be improved by early detection and intervention."

Journal • CNS Disorders • Epilepsy • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Multiple Sclerosis • Oncology

Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support in Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma With Pulmonary Involvement at Presentation. (PubMed, Cureus) - "Treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone (CHOEP) chemotherapy led to significant clinical improvement, allowing successful VV-ECMO weaning. However, the disease relapsed shortly after with a comparable severity of respiratory failure, leading to a second VV-ECMO run combined with urgent BRESHAP (brentuximab vedotin, etoposide, methylprednisolone (Solu-Medrol), high-dose cytarabine (Ara-C), and cisplatin) chemotherapy. A second relapse occurred, and the patient died 12 months after diagnosis. This case report explores the potential utility of VV-ECMO as a bridge to recovery in carefully selected patients with treatable hematologic malignancies."

Journal • Cardiovascular • Critical care • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). (PubMed, Ann Oncol) - "BRESHAP looks a safe and effective pre-transplant induction regimen, does not jeopardize transplant and allows long-term remissions and survival."

Clinical • Journal • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Thrombocytopenia • Transplantation • CD34

Bilateral optic neuropathy secondary to chronic lymphocytic leukaemia infiltration. (PubMed, BMJ Case Rep) - "The patient was treated with high-dose intravenous methylprednisolone followed by ibrutinib, resulting in marked visual recovery and normalisation of visual fields. Temporary discontinuation of ibrutinib due to neutropenia led to symptom recurrence and persistent central nervous system infiltration, which improved after treatment was resumed. This case highlights the diagnostic challenges of LON, particularly when ophthalmic and imaging findings are initially normal, and underscores the importance of CSF analysis and prompt CLL-directed therapy to prevent irreversible visual loss and achieve favourable outcomes."

Journal • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Ocular Inflammation • Oncology • Ophthalmology • Optic Neuritis • Pain

Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM). (ASCO 2023) - P2 | " Ixa-Dara naïve RRMM patients received oral Ixazomib (4 mg: days 1, 8, 15), IV Daratumumab (16 mg/kg; days 1, 8, 15, 22, cycles 1-2; days 1, 15, cycles 3-6; days 1, cycles 7+) and IV Methylprednisolone before Daratumumab (100 mg at day 1, 8, cycle 1 and then 60 mg)...Thirty-five patients (64%) were previously exposed to bortezomib, 37 (67%) were previously exposed to lenalidomide (Len) and 23 (42 %) were refractory to Len... In this elderly frail population Ixa-Dara is a feasible combination with favorable efficacy profile even in Len refractory and HR cytogenetic patients. Early toxicity remains a concern in this population eventhough more manageable with Dara SC. Late benefit is consistent with one third of patients still on treatment."

Clinical • P2 data • Anemia • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Geriatric Disorders • Hematological Disorders • Hypertension • Infectious Disease • Multiple Myeloma • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM). (ASCO 2022) - P2 | " Ixa-Dara naïve RRMM patients received oral Ixazomib (4 mg: days 1, 8, 15), IV Daratumumab (16 mg/kg; days 1, 8, 15, 22, cycles 1-2; days 1, 15, cycles 3-6; days 1, cycles 7+) and IV Methylprednisolone before Daratumumab (100 mg at day 1, 8, cycle 1 and then 60 mg)...Thirty-three patients (60%) were previously exposed to bortezomib, 37 (67%) were previously exposed to lenalidomide (Len) and 20 (36 %) were refractory to Len... In this elderly frail population Ixa-Dara is a feasible combination with favorable efficacy profile even in Len refractory and HR cytogenetic patients. Early toxicity remains a concern in this population eventhough more manageable with Dara SC."

Clinical • P2 data • Gastroenterology • Gastrointestinal Disorder • Geriatric Disorders • Hematological Disorders • Hypertension • Infectious Disease • Multiple Myeloma • Respiratory Diseases • Septic Shock • Thrombocytopenia

Ramsay Hunt Syndrome Following Vedolizumab Initiation in Refractory Ulcerative Colitis (ACG 2026) - "He was treated with intravenous methylprednisolone and valacyclovir followed by oral prednisone and valacyclovir at discharge. His UC had been refractory to multiple therapies including infliximab and a recent 3-year course of tofacitinib...Vedolizumab was discontinued, and he was transitioned to risankizumab-rzaa with improved UC control and weight gain...Figure: Figure 1. White-mucocutaneous lesions on the right side of the patientâs hard palate, consistent with Ramsay Hunt Syndrome."

Cardiovascular • CNS Disorders • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Otorhinolaryngology • Ulcerative Colitis • Varicella Zoster

Presence of Antinuclear Antibodies in the Cerebrospinal Fluid and in the Serum in a Patient With Sjögren's Syndrome and Systemic Lupus: A Case Report. (PubMed, Case Reports Immunol) - "Hydroxychloroquine (HCQ) had been discontinued 4 months prior due to HCQ-related optic neuropathy confirmed on optical coherence tomography (OCT)...The patient received intravenous methylprednisolone (500 mg/day × 3 days) followed by oral corticosteroids, with leflunomide added as an immunomodulatory agent given the overlap syndrome context, resulting in a favourable clinical outcome. The absence of intrathecal immunoglobulin synthesis and oligoclonal bands supports blood-brain barrier dysfunction rather than a primary demyelinating process, highlighting the diagnostic challenge in SLE-SS overlap. ANA detection in CSF may serve as a supportive marker for neuropsychiatric lupus (NPSLE) in overlap syndromes."

Journal • Bronchiectasis • Immunology • Inflammatory Arthritis • Lupus • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Psychiatry • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome • Systemic Lupus Erythematosus